Guggenheim Capital
EWTX icon

Guggenheim Capital’s Edgewise Therapeutics EWTX Stock Holding History

Guggenheim Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Buy
13,649
+2,125
+18% +$73.3K ﹤0.01% 1246
2026
Q1 		$363K Buy
11,524
+953
+9% +$27.5K ﹤0.01% 1314
2025
Q4 		$262K Buy
+10,571
New +$212K ﹤0.01% 1586

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Guggenheim Capital's EWTX Position: Q2 2026 in Review

Guggenheim Capital increased its Edgewise Therapeutics (EWTX) stake by 18% in Q2 2026, buying an estimated $73.3K and bringing the position to 13,649 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #1246.

Guggenheim Capital first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Guggenheim Capital held 13,649 shares of Edgewise Therapeutics worth $555K as of Q2 2026.
  • Guggenheim Capital bought 2,125 Edgewise Therapeutics shares in Q2 2026, an estimated $73.3K.
  • Edgewise Therapeutics made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1246 holding.
  • Guggenheim Capital first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.